Stockhead – PharmAust plans for pivotal Phase 2/3 trial after key quarter of milestones MediaBy Nickholas Bahr01/05/2024
Small Caps – PharmAust gears for major clinical milestones in 2024, following strong start and FDA feedback MediaBy Nickholas Bahr30/04/2024
Small Caps – PharmAust appoints interim CEO as company plans for pivotal Phase 2/3 study MediaBy Nickholas Bahr23/04/2024
Stockhead – PharmAust bolsters manufacturing leadership to expand path to commercialisation MediaBy Nickholas Bahr18/04/2024
Small Caps – PharmAust appoints industry veteran to spearhead manufacturing ahead of critical MPL trial MediaBy Nickholas Bahr18/04/2024
Stockhead – PharmAust inks approval from Macquarie University for Open-Label MND extension study MediaBy Nickholas Bahr10/04/2024
Small Caps – PharmAust’s pioneering monepantel MND study receives HREC green light for final phase MediaBy Nickholas Bahr10/04/2024
The West – How PharmAust is offering hope to patients with MND and ALS using veterinary drug monepantel MediaBy Nickholas Bahr02/04/2024
Best Stocks – Revolutionizing ALS Treatment: New Findings Reveal Potential Game-Changer in Disease Management MediaBy Nickholas Bahr19/03/2024